Stay Informed
Medical Links
- 2010 Alzheimer's Disease Facts and Figures - updated facts for 2010 on AD
- Abbott Laboratories
- Adult Care Advisors
- Alcoeur Gardens - Special care for the Alzheimer’s Disease patient
- Alzheimer’s Disease information provided by Novartis Pharmaceuticals - For patients and caregivers
- Alzheimer’s Foundation of America
- Alzheimer’s Foundation of America - Support resource for patients, cargivers and health care professionals
- Alzheimer’s Disease Clinical Trials
- Bristol-Myers Squibb Prodromal AD study
- CLINICAL RESEARCH TRIALS IN ALZHEIMER'S DISEASE - All current AD trials in the United States
- Clinical Trials at Memory Enhancement Centers of America - Clinical Research Trials
- COVANCE
- Dr Danov : Neuropsychologist PC - Pediatric and Adult Neuropsychology
- Eisai
- Elan Corporation
- Geriatric Medical Center of Dr. Sanjiv, Sharma, MD - First class geriatric medical care for seniors
- ICON Central Laboratories
- Lori Wright Consulting - CNS research consulting firm
- Neuronascent
- Novartis
- Pfizer
- Quintiles
- Sanofi-Aventis
- The Regency at Dover (Toms River, NJ) - “A Premier Senior Club”
- Wyeth Pharmaceuticals
Links
Search
 |
Joel S. Ross, MD |
MD FACP AGSF CMD CPI |
President and Founder |
Memory Enhancement Center |
of America, Inc. |
4 Industrial Way West, 2nd Floor |
Eatontown, New Jersey 07724 |
732.571.1535 |
« “The Alzheimer’s Project” | Home | 21st Century Approach to Preserving Memory & Alzheimer’s Disease Prevention »
Spinal Fluid Biomarkers can predict risk of developing Alzheimer’s Disease: Huge breakthrough likely!!!
By Joel Ross | May 25, 2009
Latest Updates From The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Alzheimer imaging aficionados thronged to back-to-back meetings held recently in Seattle for a preview of the latest data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Launched in the fall of 2004 and set to conclude next year, the $64-million ADNI is comparing imaging methods and fluid biomarkers in the same set of people to determine which measures can best predict and track Alzheimer-disease clinical changes over time. The project is approaching the homestretch of data collection. By the fall of 2010, ADNI scientists will have collected three years of longitudinal data from more than 800 participants (about 200 normal, 400 with mild cognitive impairment (MCI), and 200 with Alzheimer disease) at 59 U.S. and Canadian sites. The Seattle meetings featured preliminary analysis of the one-year data.
By and large, ADNI has helped identify a number of precise, clinically meaningful biomarkers that should be able to stand in for slower-to-budge cognitive measures, slashing time and cost from AD drug trials. “I think that ADNI is not only on track for meeting the goals we set out with, but we’ve added so many additional goals,” said principal investigator Michael Weiner, University of California, San Francisco, in a post-meeting phone conversation with this reporter. “The whole project has become more ambitious and is having more impact.”
The Alzheimer Research Forum, founded in 1996, is the web’s most dynamic scientific community dedicated to understanding Alzheimer disease and related disorders. Access to the web site is free to all. The Forum’s editorial priorities are as diverse as the needs of the research community. The web site reports on the latest scientific findings, from basic research to clinical trials; creates and maintains public databases of essential research data and reagents; and produces discussion forums to promote debate, speed the dissemination of new ideas, and break down barriers across the numerous disciplines that can contribute to the global effort to cure Alzheimer’s disease.
The Alzheimer Research Forum is an independent nonprofit organization supported by grants and individual donations. The web site does not endorse any specific product or scientific approach.
Source: Alzheimer Research Forum Foundation
Topics: Uncategorized | No Comments »